Cannabis Industry Outlook 2027|Key Themes|10 min read

Five themes that will shape cannabis in 2027

Twelve experts made 36 predictions independently. Read together, they point to a year in which evidence, medicine and consolidation matter more than headlines, with one large question left open.

At a glance

Share of the panel whose predictions support each theme.

  1. Evidence replaces argument

    Pilot markets and large clinical trials will give regulators real data for the first time.

    9 of 12 experts
  2. Medical-first becomes the global default

    New markets will open through medicine and exports, not adult-use retail.

    8 of 12 experts
  3. Capital consolidates before it expands

    Fewer, larger operators. Mergers will outpace new entrants.

    7 of 12 experts
  4. Products must prove their claims

    CBD and minor cannabinoids will compete on evidence and quality, not marketing.

    6 of 12 experts
  5. The open question: US rescheduling

    The panel’s sharpest split. Five expect real change in 2027; seven do not.

    5 vs 7 divided

01Evidence replaces argument

9 of 12 experts made a related prediction

For most of the past decade, cannabis policy has been debated on assumptions. The panel expects that to change in 2027. Regional pilot markets in Europe will produce a full year of sales data, and several large clinical trials will report results.

Experts in policy and medicine reached the same conclusion from different directions: regulators, doctors and investors will finally be able to point to numbers rather than estimates.

“Europe has argued about cannabis for decades without evidence. 2027 is the year the evidence arrives.”
Dr. Miriam Keller, Policy & Law, Germany

02Medical-first becomes the global default

8 of 12 experts made a related prediction

Outside North America, the panel sees few new adult-use markets opening in 2027. Instead, governments will expand medical access, tighten standards and build export industries around pharmaceutical-grade production.

Several experts described this as the politically safest route: it creates jobs and tax revenue while keeping the public debate focused on patients.

03Capital consolidates before it expands

7 of 12 experts made a related prediction

After years of falling prices and tight credit, investors on the panel expect 2027 to be a year of mergers rather than launches. Operators with strong balance sheets will buy distressed competitors, and new capital will favour proven businesses over start-ups.

04Products must prove their claims

6 of 12 experts made a related prediction

Consumer products face a tougher year. Regulators are expected to enforce limits on health claims, and buyers are becoming more sceptical. The experts predict that brands able to show testing, dosing accuracy and clinical support will win share from those relying on marketing.

05The open question: US rescheduling

5 vs 7 the panel is divided

No topic divided the panel more. Five experts expect rescheduling in the United States to bring meaningful change in 2027, most visibly in banking and taxation. Seven believe legal challenges and slow implementation will push the real impact into 2028 or later.

Both camps agree on one point: whatever happens in Washington will move capital markets worldwide.

Themes are identified by the editors from the experts’ submitted predictions. An expert is counted toward a theme when at least one of their three predictions directly supports it. Content is for information only and does not constitute investment, legal or medical advice. Experts and figures shown are sample content.